Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

[1]  D. Bienfang,et al.  Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial , 2017, Chest.

[2]  L. Morel.  Immunometabolism in systemic lupus erythematosus , 2017, Nature Reviews Rheumatology.

[3]  G. Tsokos,et al.  Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus , 2017, Arthritis & rheumatology.

[4]  J. Powell,et al.  Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation , 2017, The Journal of Immunology.

[5]  N. Huang,et al.  Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years , 2016, Current Rheumatology Reports.

[6]  S. Landas,et al.  Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus‐Prone Mice , 2016, Arthritis & rheumatology.

[7]  Jianguo Xia,et al.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.

[8]  D. Gladman,et al.  Dyslipidemia in systemic lupus erythematosus: just another comorbidity? , 2016, Seminars in arthritis and rheumatism.

[9]  A. Perl.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases , 2016, Nature Reviews Rheumatology.

[10]  J. Asara,et al.  Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin , 2015, Metabolomics.

[11]  G. Canaud,et al.  Inhibition of the mTORC pathway in the antiphospholipid syndrome. , 2014, The New England journal of medicine.

[12]  C. Ponticelli.  The pros and the cons of mTOR inhibitors in kidney transplantation , 2014, Expert review of clinical immunology.

[13]  A. Perl.  Oxidative stress in the pathology and treatment of systemic lupus erythematosus , 2013, Nature Reviews Rheumatology.

[14]  S. Faraone,et al.  Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus , 2013, The Journal of Immunology.

[15]  F. Middleton,et al.  HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE , 2013, Annals of the rheumatic diseases.

[16]  Stephen V Faraone,et al.  N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[17]  Hongbo Chi,et al.  Regulation and function of mTOR signalling in T cell fate decisions , 2012, Nature Reviews Immunology.

[18]  V. Strand,et al.  Measuring outcomes in systemic lupus erythematosus clinical trials , 2011, Expert review of pharmacoeconomics & outcomes research.

[19]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[20]  M. Punaro,et al.  Minimal clinically important differences of disease activity indices in childhood‐onset systemic lupus erythematosus , 2010, Arthritis care & research.

[21]  Glinda S Cooper,et al.  Understanding the epidemiology and progression of systemic lupus erythematosus. , 2010, Seminars in arthritis and rheumatism.

[22]  I. Bruce,et al.  The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients , 2010, Rheumatology.

[23]  M. Petri,et al.  Novel evidence-based systemic lupus erythematosus responder index. , 2009, Arthritis and rheumatism.

[24]  A. Perl,et al.  Pharmacotherapy of systemic lupus erythematosus , 2009, Expert opinion on pharmacotherapy.

[25]  F. Middleton,et al.  Activation of Mammalian Target of Rapamycin Controls the Loss of TCRζ in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation1 , 2009, The Journal of Immunology.

[26]  A. Perl,et al.  Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[27]  M. Mamzer-Bruneel,et al.  Brief Communication: Sirolimus-Associated Pneumonitis: 24 Cases in Renal Transplant Recipients , 2006, Annals of Internal Medicine.

[28]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[29]  M. Lockshin,et al.  Treatment of the antiphospholipid syndrome. , 2003, The New England journal of medicine.

[30]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[31]  A. Perl.  Mechanisms of viral pathogenesis in rheumatic disease , 1999, Annals of the rheumatic diseases.

[32]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[33]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[34]  L. Adams,et al.  Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. , 1994, Arthritis and rheumatism.

[35]  S. Sehgal,et al.  Rapamycin: In Vitro Profile of a New Immunosuppressive Macrolide. , 1993, Annals of the New York Academy of Sciences.

[36]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[37]  S. Thiru,et al.  Rapamycin in experimental renal allografts in dogs and pigs. , 1990, Transplantation proceedings.

[38]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[39]  J. Goust,et al.  Systemic lupus erythematosus. , 1976, Immunology series.

[40]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[41]  D A Isenberg,et al.  Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus , 2005 .

[42]  A. Perl,et al.  Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. , 2002, Arthritis and rheumatism.